- News Library
- Servier Medical Art
- Partnering & Licensing
Servier inaugurates its subsidiary in Colombia26/03/2014
Bogotá, Colombia, March 25, 2014: Today, Servier, the leading independent French pharmaceutical group, inaugurated its new subsidiary in Latin America, Servier Colombia, in the presence of the French Ambassador, Mr Jean-Marc Laforêt, and representatives of various Colombian public and private institutions and learned and medical societies.
With the launch of Servier Colombia, some forty jobs have been created in Bogotá, Medellín, Barranquilla, and Cali. Many of the people concerned – physicians, engineers, pharmacists, scientists, and administrative staff – are graduates of the various Colombian universities. For Pierre Faraldo, Servier’s Director for Latin America, “The high quality of Colombia’s universities is a major asset for a company like Servier, which has a large scientific staff. The future development of Servier Colombia through the launch of new drugs will result in a significant increase in employment across the country.”
Servier Colombia intends to bring true added value to the drug market in Colombia, particularly in the fields of cardiovascular diseases, diabetes, depression, and bone and joint diseases, with oncology in the near future. During the inauguration, Régis Fedrigo, General Director of Servier Colombia, expressed “The wish to participate in optimizing the treatment of Colombian patients, in close collaboration with health professionals, thanks to medical innovation contributed by Servier drugs”.
Today, Servier is present in every country in Latin America, where it is one of the 15 largest research laboratories with, in particular, strong activity in Brazil, Venezuela, Argentina, Central America, and Mexico. Growth has been very high there, averaging 15% per year over the last 5 years. Servier’s ambition is to increase this momentum and exceed 20% growth in 2014.
Founded in 1954, Servier is an independent French pharmaceutical research company. Its development is based on the continuous pursuit of innovation in the therapeutic areas of cardiovascular, metabolic, neurologic, psychiatric, bone and joint diseases, as well as cancer. In 2013, the company recorded a turnover of 4.2 billion euros.
- 91% of Servier drugs are consumed outside of France.
- 27% of turnover from Servier drugs were reinvested in Research and Development in 2013.
- With a strong international presence in 140 countries, Servier employs more than 21 000 people worldwide.
- The Servier Group contributed 35% to the 2013 French trade surplus in the pharmaceuticals sector.